Smooth AdCom Passage Expected For Novo's Semaglutide Despite Retinopathy Queries

 
• By Lucie Ellis-Taitt

Novo Nordisk's Victoza follow-on semaglutide, forecast to become the third once-weekly GLP-1 product available on the highly competitive US diabetes market, is expected to secure a market-leading spot, by revenue, before 2025.

Monorail
Novo's semaglutide is speeding towards US launch before end of 2017 • Source: Shutterstock

More from Alimentary/Metabolic

More from Therapy Areas